IL6 and congenital rubella syndrome: Our review of the literature revealed no fatal case among 14 patients who received the IL-6 inhibitor, tocilizumab, for CRS/HLH treatment, while the fatality rate was 14% in the patients for which anti-IL-6 treatment was not reported.